Interní Med. 2007; 9(7): 319-323

The treatment of hypertension in dialyzed patients

MUDr. Marta Nedbálková, doc. MUDr. Miroslav Souček CSc
II. interní klinika FN u sv. Anny LF MU, Brno

Hypertension in chronically dialyzed patients is a frequent complication effecting their cardiovascular morbidity and mortality. The therapy is based on salt and fluid restriction, dietary phosphate restriction and treatment with phosphate binders, correct dialysis strategy and antihypertensive medications. High salt intake and high sodium concentration in dialysis fluid are connected with thirst and increased intake of fluid and it leads with decreased residual diuresis to fluid retention. During dialysis it is necessary to reach optimal dry weight, i. e. body weight without fluid surplus. Sufficient length of dialysis provides ultafiltration of fluid excess with episodes of hypotension. If diet and optimal dry weight are not sufficient to reach the target blood pressure (< 140/90 mmHg), then antihypertensive medications are prescribed. Medications blocking the renin-angiotensin system are the treatment of choice. They decrease mortality of dialysed patients, reduce left ventricular hypertrophy, decrease sympathetic activity and improve endothelial function and decrease oxidative stress. Some antihypertensive medications (some ACE-inhibitors and beta-blockers) are removed by dialysis that is why it is necessary to adjust the medication juice and timing of aplication. We need another controlled clinical study to find an optima treatment of hypertension in dialyse patients.

Keywords: dialysis therapy, hypertension, diet, dry weight, blocker of renin-angiotensin system

Published: December 18, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nedbálková M, Souček M. The treatment of hypertension in dialyzed patients. Interní Med. 2007;9(7):319-323.
Download citation

References

  1. Agarwal R, Lewis RR. Prediction of hypertension in chronic hemodialysis patients. Kidney Int 2001; 60: 1982-1989. Go to original source... Go to PubMed...
  2. Baumgart P, Walger P, Gemen S et al. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 1991; 57: 293-298. Go to original source... Go to PubMed...
  3. Conion PJ, Walshe JJ, Heinle SK et al. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658-2663. Go to original source... Go to PubMed...
  4. Duranti E, Imperiali P, Sasdelli M et al. Is hypertension a mortality risk factor in dialysis? Kidney Int 1996; 55: S173-S174. Go to PubMed...
  5. Foley RN, Herzog CA, Collins AJ et al. Blood pressure and long-term mortality in United States hemodialysis patients. Kidney Int 2002; 62: 1784-1790. Go to original source... Go to PubMed...
  6. Hörl MP, Hörl WH. Hemodialysis-associated hypertension pathophysiology and therapy. Am J kidney Dis 2002; 39: 227-244. Go to original source... Go to PubMed...
  7. Hörl MP, Hörl WH. Hypertension and Dialysis. Kidney Blood Press Res 2003; 26: 76-81. Go to original source... Go to PubMed...
  8. Charra B, Bergstrom J, Scribner BH et al. Blood pressure control in dialysis patients: the importance of the lag phenomen. Am J Kidney Dis 1998; 32: 720-724. Go to original source... Go to PubMed...
  9. Chazot C, Charra B, Laurent G et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995; 10: 831-837.
  10. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverese epidemiology of hypertension and cardiovascular death in the hemodialysis population. Hypertension 2005; 45: 811-817. Go to original source... Go to PubMed...
  11. Kestenbaum B, Gillen DL, Sherrard DJ et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61: 2157-2164. Go to original source... Go to PubMed...
  12. Ketteler M, Floege J. Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scene. Nephrol Dial Transplat 2006; 21: 33-35. Go to original source... Go to PubMed...
  13. Kooman JP, Gladziwa U, Böcker G et al. Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values. Nephrol Dial Transplant 1992; 7: 917-923. Go to original source... Go to PubMed...
  14. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? Am J Kidney Dis 1998; 32: 853-906. Go to original source... Go to PubMed...
  15. Li PK, Chow KM, Wong TY et al. Preservation of residual renal function in peritoneal dialysis patients by angiotensin-converting enzyme inhibitor. A prospective randomized study. J Am Soc Nephrol 2002; 13: F-FC004.
  16. Locatelli F, Covic A, Chazot C et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19: 1058-1068. Go to original source... Go to PubMed...
  17. London GM. Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrol Dial Transplant 2001; 16: 475-478. Go to original source... Go to PubMed...
  18. Mazzuchi N, Carbonell E, Fernandez-Cean J et al. Importance of blood pressure control in hemodialysis survival. Kidney Int 2000; 58: 2147-2154. Go to original source... Go to PubMed...
  19. Menon MK, Naimark DM, Bargman JM et al. Long term blood pressure control on a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-2213. Go to original source... Go to PubMed...
  20. Peixoto AJ, White WB. Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevance. Curr Opin Nephrol Hypertens 2002; 11: 507-516. Go to original source... Go to PubMed...
  21. Ritz E, Schwenger V, Zeier M et al. Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant 2001; 16: 1550-1554. Go to original source... Go to PubMed...
  22. Santos S, Peixoto AJ. Hypertension in dialysis. Curr Opin Nephrol Hypertens 2005; 14: 111-118. Go to original source... Go to PubMed...
  23. Santos SF, Mendes RB, Santos CA et al. Profile of interdialytic blood pressure in hemodialysis patients. Am J Nephrol 2003; 23: 96-105. Go to original source... Go to PubMed...
  24. Sobotová D. Hypertenze při chronickém selhání ledvin a pravidelném dialyzačním léčení. Kardiologické forum 2006; 4: 36-38.
  25. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative: Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 (Suppl 3): 16-153. Go to original source...
  26. Tozawa M, Iseki K, Iseki C et al. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61: 717-726. Go to original source... Go to PubMed...
  27. U. S. Renal Data System: USRDS 1998 Annual Data Report, 1998.
  28. Xu J, Li G, Wang P et al. Renalase: a novel, soluble monoamine oxidase that regulates blood pressure. J Am Soc Nephrol 2005; 16: 2521-2527. Go to original source...
  29. Zager PG, Nicolic J, Brown RH et al. U curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561-569. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.